BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

501 related articles for article (PubMed ID: 30463262)

  • 1. Natural Killer Cell Dysfunction in Hepatocellular Carcinoma: Pathogenesis and Clinical Implications.
    Sung PS; Jang JW
    Int J Mol Sci; 2018 Nov; 19(11):. PubMed ID: 30463262
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Natural killer cells in hepatocellular carcinoma: current status and perspectives for future immunotherapeutic approaches.
    Yu M; Li Z
    Front Med; 2017 Dec; 11(4):509-521. PubMed ID: 28780700
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Natural killer cell dysfunction in hepatocellular carcinoma and NK cell-based immunotherapy.
    Sun C; Sun HY; Xiao WH; Zhang C; Tian ZG
    Acta Pharmacol Sin; 2015 Oct; 36(10):1191-9. PubMed ID: 26073325
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Monocyte/macrophage-elicited natural killer cell dysfunction in hepatocellular carcinoma is mediated by CD48/2B4 interactions.
    Wu Y; Kuang DM; Pan WD; Wan YL; Lao XM; Wang D; Li XF; Zheng L
    Hepatology; 2013 Mar; 57(3):1107-16. PubMed ID: 23225218
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trichostatin A Sensitizes Hepatocellular Carcinoma Cells to Enhanced NK Cell-mediated Killing by Regulating Immune-related Genes.
    Shin S; Kim M; Lee SJ; Park KS; Lee CH
    Cancer Genomics Proteomics; 2017; 14(5):349-362. PubMed ID: 28871002
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Natural Killer Cells in Liver Disease and Hepatocellular Carcinoma and the NK Cell-Based Immunotherapy.
    Liu P; Chen L; Zhang H
    J Immunol Res; 2018; 2018():1206737. PubMed ID: 30255103
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel natural killer cell-mediated cancer immunotherapeutic activity of anisomycin against hepatocellular carcinoma cells.
    Kim M; Lee SJ; Shin S; Park KS; Park SY; Lee CH
    Sci Rep; 2018 Jul; 8(1):10668. PubMed ID: 30006566
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expanded and Activated Natural Killer Cells for Immunotherapy of Hepatocellular Carcinoma.
    Kamiya T; Chang YH; Campana D
    Cancer Immunol Res; 2016 Jul; 4(7):574-81. PubMed ID: 27197065
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Down-regulation of PR/SET domain 10 underlies natural killer cell dysfunction in hepatocellular carcinoma.
    Han J; Ke C; Jiang B; Zhou H; Xu H; Xie X
    Clin Exp Immunol; 2021 Dec; 206(3):366-377. PubMed ID: 34562314
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of Enhancer of zeste homolog 2 (EZH2) induces natural killer cell-mediated eradication of hepatocellular carcinoma cells.
    Bugide S; Green MR; Wajapeyee N
    Proc Natl Acad Sci U S A; 2018 Apr; 115(15):E3509-E3518. PubMed ID: 29581297
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MiR-506 Promotes Natural Killer Cell Cytotoxicity against Human Hepatocellular Carcinoma Cells by Targeting STAT3.
    Su Z; Ye X; Shang L
    Yonsei Med J; 2019 Jan; 60(1):22-29. PubMed ID: 30554487
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The interactions between major immune effector cells and Hepatocellular Carcinoma: A systematic review.
    Schoenberg MB; Li X; Li X; Han Y; Börner N; Koch D; Guba MO; Werner J; Bazhin AV
    Int Immunopharmacol; 2021 Dec; 101(Pt A):108220. PubMed ID: 34673334
    [TBL] [Abstract][Full Text] [Related]  

  • 13. hIL-15 gene-modified human natural killer cells (NKL-IL15) augments the anti-human hepatocellular carcinoma effect in vivo.
    Jiang W; Zhang C; Tian Z; Zhang J
    Immunobiology; 2014 Jul; 219(7):547-53. PubMed ID: 24721706
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatocellular carcinoma-associated fibroblasts trigger NK cell dysfunction via PGE2 and IDO.
    Li T; Yang Y; Hua X; Wang G; Liu W; Jia C; Tai Y; Zhang Q; Chen G
    Cancer Lett; 2012 May; 318(2):154-61. PubMed ID: 22182446
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CNOT7 depletion reverses natural killer cell resistance by modulating the tumor immune microenvironment of hepatocellular carcinoma.
    Ren C; Ren X; Cao D; Zhao H; Zhai Z; Li H; Li Y; Fu X; He J; Zhao H
    FEBS Open Bio; 2020 May; 10(5):847-860. PubMed ID: 32160402
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NK cell receptor imbalance and NK cell dysfunction in HBV infection and hepatocellular carcinoma.
    Sun C; Sun H; Zhang C; Tian Z
    Cell Mol Immunol; 2015 May; 12(3):292-302. PubMed ID: 25308752
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Natural Killer Cells and Regulatory T Cells Cross Talk in Hepatocellular Carcinoma: Exploring Therapeutic Options for the Next Decade.
    Bozward AG; Warricker F; Oo YH; Khakoo SI
    Front Immunol; 2021; 12():643310. PubMed ID: 33995362
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adoptive transfer of TRAIL-expressing natural killer cells prevents recurrence of hepatocellular carcinoma after partial hepatectomy.
    Ohira M; Ohdan H; Mitsuta H; Ishiyama K; Tanaka Y; Igarashi Y; Asahara T
    Transplantation; 2006 Dec; 82(12):1712-9. PubMed ID: 17198265
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comprehensive characterization of tumor infiltrating natural killer cells and clinical significance in hepatocellular carcinoma based on gene expression profiles.
    Wu M; Mei F; Liu W; Jiang J
    Biomed Pharmacother; 2020 Jan; 121():109637. PubMed ID: 31810126
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A bispecific protein rG7S-MICA recruits natural killer cells and enhances NKG2D-mediated immunosurveillance against hepatocellular carcinoma.
    Wang T; Sun F; Xie W; Tang M; He H; Jia X; Tian X; Wang M; Zhang J
    Cancer Lett; 2016 Mar; 372(2):166-78. PubMed ID: 26791237
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.